Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? (RIPCORD 2)

A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.

A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).

Studieoversikt

Detaljert beskrivelse

The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

Studietype

Intervensjonell

Registrering (Faktiske)

1100

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bristol, Storbritannia, BS2 8HW
        • Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust
    • Dorset
      • Bournemouth, Dorset, Storbritannia, BH7 7DW
        • Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
    • East Sussex
      • Brighton, East Sussex, Storbritannia, BN2 5BE
        • Brighton and Sussex University Hospitals NHS Trust
    • Hampshire
      • Portsmouth, Hampshire, Storbritannia, PO6 3LY
        • Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
      • Southampton, Hampshire, Storbritannia, SO16 6YD
        • Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
    • Lancashire
      • Blackburn, Lancashire, Storbritannia, BB2 3HH
        • Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
    • Merseyside
      • Liverpool, Merseyside, Storbritannia, L14 3PE
        • Liverpool Heart and Chest Hospital NHS Foundation Trust
    • Northumberland
      • Newcastle upon Tyne, Northumberland, Storbritannia, NE7 7DN
        • Freeman Hospital - Newcastle Hospitals
    • Nottinghamshire
      • Mansfield, Nottinghamshire, Storbritannia, NG17 4JL
        • King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
      • Nottingham, Nottinghamshire, Storbritannia, NG5 1PB
        • City Hospital - Nottingham University Hospitals NHS Trust
    • Scotland
      • Glasgow, Scotland, Storbritannia, G81 4DY
        • Golden Jubilee National Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Storbritannia, S5 7AU
        • Northern General Hospital - Sheffield Teaching Hospitals
    • Staffordshire
      • Stoke-on-Trent, Staffordshire, Storbritannia, ST4 6QG
        • Royal Stoke University Hospital - University Hospitals of North Midlands
    • West Midlands
      • Birmingham, West Midlands, Storbritannia, B15 2TH
        • Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
    • West Yorkshire
      • Wakefield, West Yorkshire, Storbritannia, WF1 4DG
        • Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
    • Yorkshire
      • Hull, Yorkshire, Storbritannia, HU16 5JQ
        • Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
      • Leeds, Yorkshire, Storbritannia, LS1 3EX
        • Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

· Inclusion criteria

o Outline Initial Inclusion Criteria (before entry to cath lab):

Patient scheduled for coronary angiography for the:

  • Elective investigation of known or suspected coronary artery disease OR
  • Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event

    o Outline Angiographic Inclusion Criterion (after angiography):

  • Presence of significant coronary disease defined as:

Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter.

  • Key Exclusion Criteria

    • Screening phase exclusion criteria:

      • ≤ 18 years of age
      • Previous enrolment in this trial
      • Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU)
      • Inability to provide informed consent
      • Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year
      • Non-cardiac pathology that may limit survival in the next year
      • Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery)
      • Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy
      • Hypertrophic cardiomyopathy
      • Previous coronary artery surgery of any type
      • Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45
      • Anaemia with a current measured haemoglobin of < 100
      • Angiography performed in the context of an ST elevation myocardial infarction event
      • Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block
      • Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms
      • Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory
      • Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease
      • Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning.
      • Active bleeding at the time of planned index angiography
      • Pregnant women
    • Angiographic phase exclusion criteria:

      • Single vessel occlusive coronary disease (TIMI flow <3) as sole disease
      • Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example:

        • Patient discomfort
        • Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention
        • Significant use of radiographic contrast or X-Ray exposure during the initial angiography
        • Inadequate angiographic images or failure to intubate any of the coronary vessels
        • Aorto-ostial disease that would preclude accurate assessment of FFR
        • Insufficient laboratory time
        • Uncertain availability of key clinical and trial staff
        • PW use in coronaries declared unsafe (e.g. tight or long disease)
        • PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Conventional angiography
Routine angiography will be performed according to local best practice
Eksperimentell: Routine Measurement of FFR
Additional investigation with the measurement of FFR in all major vessels
FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
Andre navn:
  • Pressure wire assessment

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Primary Economic Outcome Measure
Tidsramme: One year
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
One year
Primary Quality of Life Outcome Measure
Tidsramme: One year
Patient reported quality of life at one year using the EQ-5D health questionnaire.
One year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dødelighet av alle årsaker
Tidsramme: Ett år
Ett år
Management strategy information
Tidsramme: Reported once: Single declaration at index procedure after randomisation
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Management strategy information
Tidsramme: Reported once: Single declaration at index procedure after randomisation
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Angina symptoms
Tidsramme: One year
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
One year
Angina symptoms
Tidsramme: One year
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
One year
Number of hospitalisation events
Tidsramme: One year
One year
Total hospital days
Tidsramme: One year
One year
Hospitalisation events
Tidsramme: One year
Hospitalisation events coded as cerebro-vascular accident (CVA).
One year
Hospitalisation events
Tidsramme: One year
Hospitalisation events coded as myocardial infarction.
One year
Hospitalisation events
Tidsramme: One year

Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of:

  • Planned revascularisation - if declared as the index strategy.
  • All additional revascularisation events.
One year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nicholas Curzen, BM PhD FRCP, University Hospital Southampton NHS Foundation Trust
  • Hovedetterforsker: Rod H Stables, MA, DM, BM BCH, FRCP, Liverpool Heart and Chest Hospital NHS Foundation Trust

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2016

Primær fullføring (Forventet)

1. desember 2019

Studiet fullført (Forventet)

1. mars 2020

Datoer for studieregistrering

Først innsendt

6. juli 2016

Først innsendt som oppfylte QC-kriteriene

1. september 2016

Først lagt ut (Anslag)

8. september 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. august 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. august 2019

Sist bekreftet

1. august 2019

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere